Autologous dendritic cell based cancer vaccine, produced from patient¡¯s peripheral blood mononuclear cells (PBMC) by differentiating into dendritic cells after sensitizing with tumor lysate and KLH(Keyhole Limpet Hemocyanin). Once CreaVax-RCC? are injected, the equipped DCs move to the regional lymph nodes to modulate immune response such as induction of cancer-specific cytotoxic T lymphocytes (CTL) to kill tumor cells. CreaVax-RCC? have received tentative approval (2007) and product manufacture license as export product (2013) from MFDS.